Instrument Inactif

Communiqués RegeneRx Biopharmaceuticals, Inc. Other OTC

Actions

RGRX

US75886X1081

Recherche biotechnologique et médicale

Communiqués

16/08/23	RegeneRx Effects Reverse Stock Split and Terminates SEC Reporting Obligations	AQ
07/08/23	RegeneRx Receives Stockholder Approval for Reverse Stock Split	PR
07/08/23	RegeneRx Biopharmaceuticals : Submission of Matters to a Vote of Security Holders - Form 8-K	PU
01/08/23	RegeneRx To Extend Consent Solicitation Vote	PR
14/04/23	RegeneRx Biopharmaceuticals, Inc. - First Patient Enrolled into U.S. Phase 3 Neurotrophic Keratitis Clinical trial with RGN-259	AQ
13/04/23	First Patient Enrolled into U.S. Phase 3 Neurotrophic Keratitis Clinical Trial with RGN-259	PR
11/04/23	RegeneRx Issues Letter To Stockholders	PR
11/04/23	REGENERX BIOPHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condition and Results of Operation. (form 10-K)	AQ
31/01/23	Thymosin Beta 4 Research Leads Toward Potential Future Anti-aging Therapy	PR
03/01/23	Publication of RGN-259 Phase 3 Clinical Trial Results in Patients with Neurotrophic Keratopathy	PR
14/11/22	REGENERX BIOPHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
24/10/22	RegeneRx Licensee Submits Special Protocol Assessment to FDA for 4th Phase 3 Clinical Trial for Dry Eye Disease	PR
28/09/22	RegeneRx Partner Submits Phase 3 Protocol for Neurotrophic Keratopathy	AQ
27/09/22	RegeneRx Partner Submits Phase 3 Protocol for Neurotrophic Keratopathy (NK)	PR
22/08/22	RegeneRx Issues 2022 Letter To Stockholders	PR
12/08/22	REGENERX BIOPHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
18/07/22	RegeneRx Partner Signs LOI with Global Ophthalmology CRO for Two Phase 3 Clinical Trials in Neurotrophic Keratitis	PR
22/06/22	RegeneRx Licensee to Expand Phase 3 Clinical Trial Program with RGN-259	PR
16/05/22	REGENERX BIOPHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
04/05/22	Tβ4 Shows Potential as a Combination Treatment for Diabetes-Induced Complications of the Cornea	PR
30/03/22	REGENERX BIOPHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condition and Results of Operation. (form 10-K)	AQ
02/03/22	RegeneRx Provides Regulatory Update Regarding RGN-259	PR
14/02/22	RegeneRx Consultant to Receive Prestigious Award for Contributions in Field of Health	AQ
25/01/22	Researchers Confirm Thymosin Beta 4's Ability to Protect Eyes From Ethanol Injury	PR
13/01/22	RegeneRx Publishes Regulatory Update on RGN-259	AQ